Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 4
2007 5
2008 4
2009 3
2010 5
2011 5
2012 4
2013 5
2014 5
2015 7
2016 7
2017 4
2018 3
2019 14
2020 13
2021 15
2022 5
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: weber ms. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. Among authors: weber ms. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, Manfrini M, Model F, Mercier F, Petry C, Wing Q, Koendgen H, Smith T, Kappos L. Hauser SL, et al. Among authors: weber ms. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 15;10(2):e200094. doi: 10.1212/NXI.0000000000200094. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36792367 Free PMC article. Clinical Trial.
Targeting B cells in multiple sclerosis.
Sellebjerg F, Weber MS. Sellebjerg F, et al. Among authors: weber ms. Curr Opin Neurol. 2021 Jun 1;34(3):295-302. doi: 10.1097/WCO.0000000000000938. Curr Opin Neurol. 2021. PMID: 33782253 Review.
Immunological Aspects of Approved MS Therapeutics.
Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L, Illes Z, Warnke C, Laurent S, Weber MS, Zhang Y, Stuve O. Rommer PS, et al. Among authors: weber ms. Front Immunol. 2019 Jul 11;10:1564. doi: 10.3389/fimmu.2019.01564. eCollection 2019. Front Immunol. 2019. PMID: 31354720 Free PMC article. Review.
Immunopathogenesis of neuromyelitis optica.
Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, Stuve O. Levy M, et al. Among authors: weber ms. Adv Immunol. 2014;121:213-42. doi: 10.1016/B978-0-12-800100-4.00006-4. Adv Immunol. 2014. PMID: 24388217 Review.
119 results